ALK is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ATM status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RET is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].